Total Payments
$940.94
2024 Payments
$121.80
Companies
13
Transactions
17
Medicare Patients
3,548
Medicare Billing
$632,393
Payment Breakdown by Category
Food & Beverage$854.71 (90.8%)
Education$86.23 (9.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $854.71 | 15 | 90.8% |
| Education | $86.23 | 2 | 9.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $121.94 | 2 | $0 (2017) |
| GlaxoSmithKline, LLC. | $121.83 | 1 | $0 (2023) |
| La Jolla Pharmaceutical Company | $121.80 | 1 | $0 (2024) |
| Oxford Immunotec USA Inc | $113.86 | 1 | $0 (2019) |
| Gilead Sciences Inc | $111.86 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $77.18 | 1 | $0 (2018) |
| Astellas Pharma US Inc | $69.99 | 1 | $0 (2017) |
| ACELL, INC. | $58.82 | 1 | $0 (2019) |
| Becton, Dickinson and Company | $44.12 | 3 | $0 (2022) |
| ViiV Healthcare Company | $36.62 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121.80 | 1 | La Jolla Pharmaceutical Company ($121.80) |
| 2023 | $173.79 | 3 | GlaxoSmithKline, LLC. ($121.83) |
| 2022 | $60.36 | 4 | Becton, Dickinson and Company ($44.12) |
| 2019 | $172.68 | 2 | Oxford Immunotec USA Inc ($113.86) |
| 2018 | $77.18 | 1 | AstraZeneca Pharmaceuticals LP ($77.18) |
| 2017 | $335.13 | 6 | Merck Sharp & Dohme Corporation ($121.94) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $121.80 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 12/10/2023 | Avanos Medical | ON-Q* PUMP AND ACCESSORIES (Device) | Food and Beverage | In-kind items and services | $27.48 | General |
| Category: SURGICAL PAIN | ||||||
| 05/05/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: HIV | ||||||
| 01/26/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: VACCINES | ||||||
| 11/16/2022 | Becton, Dickinson and Company | BD Nano 2nd Gen Pen Needle (Device) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Diabetes Care | ||||||
| 09/21/2022 | Becton, Dickinson and Company | BD Nano 2nd Gen Pen Needle (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes Care | ||||||
| 07/14/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 06/16/2022 | Becton, Dickinson and Company | BD Nano 2nd Gen Pen Needle (Device) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Diabetes Care | ||||||
| 06/26/2019 | Oxford Immunotec USA Inc | TSPOT TB TEST (Device) | Food and Beverage | In-kind items and services | $113.86 | General |
| Category: Diagnostic Test | ||||||
| 01/31/2019 | ACELL, INC. | — | Food and Beverage | Cash or cash equivalent | $58.82 | General |
| 04/29/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $77.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/05/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $69.99 | General |
| 11/01/2017 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Food and Beverage | In-kind items and services | $106.43 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/07/2017 | ViiV Healthcare Company | TRIUMEQ (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: HIV | ||||||
| 06/14/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: Infectious Disease | ||||||
| 05/09/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $111.86 | General |
| Category: HCV | ||||||
| 04/20/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 726 | 1,213 | $513,140 | $138,152 |
| 2022 | 10 | 952 | 1,523 | $605,644 | $161,129 |
| 2021 | 10 | 875 | 1,508 | $540,601 | $150,824 |
| 2020 | 8 | 995 | 1,853 | $642,153 | $182,288 |
Total Patients
3,548
Total Services
6,097
Medicare Billing
$632,393
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 279 | 579 | $198,088 | $62,435 | 31.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 166 | 170 | $112,710 | $26,707 | 23.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 177 | 303 | $71,782 | $21,701 | 30.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 50 | 90 | $87,300 | $17,037 | 19.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 34 | $21,590 | $5,461 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 22 | $10,120 | $2,487 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $11,550 | $2,324 | 20.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 309 | 583 | $199,420 | $53,472 | 26.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 184 | 192 | $127,296 | $33,868 | 26.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 268 | 503 | $118,899 | $32,204 | 27.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 36 | 61 | $59,170 | $11,771 | 19.9% |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | Office | 2022 | 17 | 17 | $15,300 | $7,732 | 50.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 52 | $23,920 | $5,954 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 35 | $22,225 | $5,620 | 25.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 51 | 51 | $20,247 | $4,672 | 23.1% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2022 | 16 | 17 | $9,927 | $3,349 | 33.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $9,240 | $2,486 | 26.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 351 | 815 | $192,984 | $53,114 | 27.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 171 | 187 | $123,841 | $33,881 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 175 | 278 | $95,076 | $26,051 | 27.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 47 | 54 | $40,220 | $10,588 | 26.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 67 | $30,380 | $8,085 | 26.6% |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | Office | 2021 | 11 | 11 | $9,900 | $6,315 | 63.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 31 | $19,685 | $5,277 | 26.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $11,550 | $3,141 | 27.2% |
About Dr. Jennifer Cheng, D.O
Dr. Jennifer Cheng, D.O is a Infectious Disease healthcare provider based in Walnut Creek, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2010. The National Provider Identifier (NPI) number assigned to this provider is 1669791612.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Cheng, D.O has received a total of $940.94 in payments from pharmaceutical and medical device companies, with $121.80 received in 2024. These payments were reported across 17 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($854.71).
As a Medicare-enrolled provider, Cheng has provided services to 3,548 Medicare beneficiaries, totaling 6,097 services with total Medicare billing of $632,393. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Walnut Creek, CA
- Active Since 05/28/2010
- Last Updated 11/15/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1669791612
Products in Payments
- SHINGRIX (Biological) $121.83
- XERAVA (Drug) $121.80
- TSPOT TB TEST (Device) $113.86
- Epclusa (Drug) $111.86
- ZINPLAVA (Biological) $106.43
- FARXIGA (Drug) $77.18
- BD Nano 2nd Gen Pen Needle (Device) $44.12
- ON-Q* PUMP AND ACCESSORIES (Device) $27.48
- CABENUVA (Biological) $24.48
- VIBATIV (Drug) $19.20
- Arikayce (Drug) $16.24
- DIFICID (Drug) $15.51
- TRIUMEQ (Drug) $12.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Walnut Creek
Dr. Ronald Wasserman, M.d, M.D
Infectious Disease — Payments: $3,199
Infectious Disease $3,199
Dr. Jorge Bernett, M.d, M.D
Infectious Disease — Payments: $2,163
Infectious Disease $2,163
Dr. Joshua Perlroth, M.d, M.D
Infectious Disease — Payments: $1,104
Infectious Disease $1,104
Konark Sharma, M.d, M.D
Infectious Disease — Payments: $836.26
Infectious Disease $836.26
Nimisha Mishra-Shukla, Md, MD
Infectious Disease — Payments: $705.50
Infectious Disease $705.50
Dr. Bela Chheda, M.d, M.D
Infectious Disease — Payments: $308.18
Infectious Disease $308.18